News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
605,948 Results
Type
Article (27345)
Company Profile (212)
Press Release (578386)
Multimedia
Podcasts (72)
Webinars (22)
Section
Business (199385)
Career Advice (1086)
Deals (29874)
Drug Delivery (102)
Drug Development (63465)
Employer Resources (152)
FDA (11981)
Job Trends (11613)
News (285775)
Policy (24453)
Tag
2025 Best Places to Work (1)
2026 Best Places to Work (1)
2027 BioCapital Elite (1)
2027 BioCapital Standard (3)
2027 BioMidwest Digital (1)
2027 BioMidwest Standard (3)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (9)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (5)
2027 Genetown Elite (3)
2027 Genetown Premier (1)
2027 Genetown Standard (7)
2027 Pharm Country Digital (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (10)
40 Under 40 (2)
Academia (1856)
Academic (2)
Accelerated approval (48)
ADA (27)
Adcomms (18)
Allergies (145)
Alliances (41717)
ALS (193)
Alzheimer's disease (1479)
Antibody-drug conjugate (ADC) (488)
Approvals (12769)
Artificial intelligence (707)
ASCO (232)
Autoimmune disease (338)
Automation (58)
Bankruptcy (302)
Belgium (16)
Best Places to Work (8944)
BIO (53)
Biologics (65)
BIOSECURE Act (14)
Biosimilars (213)
BioSpace Insights (131)
Biotechnology (122)
Bispecific (36)
Bladder cancer (174)
Brain cancer (63)
Breast cancer (679)
Cancer (5352)
Cardiovascular disease (384)
Career advice (977)
Career pathing (50)
CAR-T (288)
CDC (33)
CDMO (97)
Celiac Disease (3)
Cell therapy (771)
Cervical cancer (51)
Clinical research (56916)
Collaboration (2037)
Commercialization (37)
Company closure (1)
Compensation (1670)
Complete response letters (52)
COVID-19 (1686)
CRISPR (107)
CRO (3)
C-suite (1319)
Cystic fibrosis (133)
Data (8041)
Decentralized trials (3)
Denatured (34)
Depression (152)
Dermatology (138)
Diabetes (528)
Diagnostics (5662)
Digital health (57)
Diversity (10)
Diversity, equity & inclusion (39)
Drug discovery (359)
Drug pricing (87)
Drug shortages (12)
Duchenne muscular dystrophy (248)
Earnings (80792)
Editorial (29)
Employer branding (25)
Employer resources (135)
ESMO (294)
Events (104991)
Executive appointments (1083)
Eye disease (9)
FDA (15666)
Fibrodysplasia Ossificans Progressiva (13)
Fragile X (5)
Friedreich's ataxia (22)
Frontotemporal dementia (29)
Funding (1713)
Gene editing (202)
Generative AI (53)
Gene therapy (531)
GLP-1 (681)
Government (3198)
Grass and pollen (3)
Guidances (355)
Healthcare (12994)
Hematology (125)
HIV (110)
Huntington's disease (56)
Idiopathic pulmonary fibrosis (8)
IgA nephropathy (106)
Immunology and inflammation (188)
Immuno-oncology (103)
Indications (230)
Infectious disease (1987)
Inflammatory bowel disease (205)
Inflation Reduction Act (11)
Influenza (111)
Intellectual property (315)
Interviews (163)
IPO (14071)
IRA (21)
Job creations (2915)
Job search strategy (833)
JPM (32)
Kidney cancer (26)
Kidney disease (116)
Labor market (119)
Layoffs (276)
Leadership (30)
Legal (6013)
Licensing (65)
Liver cancer (70)
Longevity (40)
Lung cancer (754)
Lung diease (11)
Lymphoma (394)
Machine learning (55)
Management (47)
Manufacturing (994)
Marketing (25)
MASH (144)
Medical affairs (4)
Medical device (10496)
Medtech (10723)
Mergers & acquisitions (17122)
Metabolic disorders (1146)
mRNA (163)
Multiple sclerosis (190)
Multispecific (4)
NASH (13)
Netherlands (21)
Neurodegenerative disease (364)
Neuropsychiatric disorders (68)
Neuroscience (2882)
Neurotech (3)
NextGen: Class of 2026 (4531)
Non-profit (2524)
Now hiring (93)
Obesity (445)
Opinion (180)
Ovarian cancer (236)
Pain (238)
Pancreatic cancer (265)
Parkinson's disease (307)
Partnered (29)
Patents (611)
Patient advocacy (5)
Patient recruitment (680)
Patient selection (60)
Peanut (53)
People (53454)
Peptides (21)
Pharmaceutical (45)
Pharmacy benefit managers (13)
Phase 1 (17895)
Phase 2 (25078)
Phase 3 (18288)
Pipeline (10583)
Policy (174)
Postmarket research (1948)
Preclinical (7959)
Press Release (70)
Prostate cancer (270)
Psychedelics (40)
Radiopharmaceuticals (272)
Rare diseases (904)
Real estate (4689)
Recruiting (64)
Regenerative medicine (20)
Regulatory (20026)
Reports (72)
Research institute (1741)
Resumes & cover letters (145)
Rett syndrome (51)
RNA editing (18)
RSV (75)
Schizophrenia (160)
Series A (305)
Series B (204)
Service/supplier (9)
Sickle cell disease (101)
Special edition (19)
Spinal muscular atrophy (122)
Sponsored (25)
Startups (3187)
State (1)
Stem cells (2)
Stomach cancer (10)
Substance use disorders (18)
Supply chain (93)
Switzerland (3)
Tariffs (36)
Tax incentives (1)
The Weekly (37)
Vaccines (739)
Venture capital (126)
Weight loss (221)
Wet AMD (5)
Women's health (137)
Worklife (22)
Date
Last 7 days (636)
Last 30 days (2200)
Last 365 days (24563)
2026 (20607)
2025 (24111)
2024 (28714)
2023 (32935)
2022 (42144)
2021 (46084)
2020 (42518)
2019 (33060)
2018 (24828)
2017 (24819)
2016 (24387)
2015 (30498)
2014 (26036)
2013 (22116)
2012 (23976)
2011 (24483)
2010 (24158)
Location
Africa (540)
Alabama (97)
Alaska (6)
Arizona (375)
Arkansas (13)
Asia (26917)
Australia (4000)
California (14287)
Canada (4155)
China (1013)
Colorado (634)
Connecticut (538)
Delaware (385)
Europe (52722)
Florida (2134)
Georgia (470)
Hawaii (5)
Idaho (51)
Illinois (984)
India (110)
Indiana (643)
Iowa (33)
Japan (564)
Kansas (126)
Kentucky (41)
Louisiana (40)
Maine (38)
Maryland (1520)
Massachusetts (9972)
Michigan (377)
Minnesota (775)
Mississippi (8)
Missouri (126)
Montana (25)
Nebraska (19)
Nevada (156)
New Hampshire (74)
New Jersey (3594)
New Mexico (25)
New York (3623)
North Carolina (1718)
North Dakota (12)
Northern California (7285)
Ohio (407)
Oklahoma (20)
Oregon (37)
Pennsylvania (2722)
Puerto Rico (28)
Rhode Island (44)
South America (739)
South Carolina (87)
South Dakota (1)
Southern California (5836)
Tennessee (181)
Texas (2449)
United States (48995)
Utah (451)
Vermont (2)
Virginia (231)
Washington D.C. (65)
Washington State (1152)
West Virginia (2)
Wisconsin (153)
Wyoming (2)
605,948 Results for "gilead sciences canada inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Inflammatory bowel disease
Gilead’s ‘highly competitive’ mid-stage ulcerative colitis data ‘validate’ I&I push
Gilead’s emvistegrast delivered greater clinical response than placebo, setting up the asset for Phase 3 testing in ulcerative colitis as well as studies in other inflammatory diseases and bolstering the company’s push beyond its HIV portfolio.
October 20, 2026
·
3 min read
·
Tristan Manalac
Press Releases
Gilead Sciences Announces Third Quarter 2026 Financial Results
October 30, 2026
·
19 min read
Immunology and inflammation
Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar
Gilead Sciences has picked up a new inflammatory disease program from China’s PepStar Therapeutics to pair with the Phase 2 inflammatory bowel disease asset emvistegrast.
October 23, 2026
·
1 min read
·
Annalee Armstrong
Licensing
Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagers
The Gilead Sciences deal, which include $135 million in upfront and near-term payments, marks a critical platform validation for Vir Biotechnology as investors await an upcoming readout in solid tumors.
October 14, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
Cognizant Expands AI-Enabled DevOps Capabilities for Gilead Sciences
October 6, 2026
·
2 min read
Press Releases
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
October 15, 2026
·
1 min read
Press Releases
Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
August 26, 2026
·
1 min read
Press Releases
Gilead Sciences Announces Second Quarter 2026 Financial Results
August 4, 2026
·
20 min read
Press Releases
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
October 5, 2026
·
6 min read
Approvals
Gilead’s TROP-2 Trodelvy, Keytruda combo win first-line FDA nods for breast cancer
Gilead’s Trodelvy can now be used as a monotherapy and in combination with Merck’s Keytruda to treat certain patients with triple-negative breast cancer.
June 25, 2026
·
1 min read
·
Tristan Manalac
1 of 60,595
Next